Skip to main content
Top
Published in: PharmacoEconomics 7/2017

01-07-2017 | Practical Application

Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis

Authors: Daisuke Goto, Ya-Chen Tina Shih, Pascal Lecomte, Melvin Olson, Chukwukadibia Udeze, Yujin Park, C. Daniel Mullins

Published in: PharmacoEconomics | Issue 7/2017

Login to get access

Abstract

Achieving comprehensive patient centricity in cost-effectiveness analyses (CEAs) requires a statistical approach that accounts for patients’ preferences and clinical and demographic characteristics. Increased availability and accessibility of patient-level health-related utility data from clinical trials or observational database provide enhanced opportunities to conduct more patient-centered CEA. Regression-based approaches that incorporate patient-level data hold great promise for enhancing CEAs to be more patient centered; this paper provides guidance regarding two CEA approaches that apply regression-based approaches utilizing patient-level health-related utility and costs data. The first approach utilizes patient-reported preferences to determine patient-specific utility. This approach evaluates how individuals’ unique clinical and demographic factors affect their utility and cost levels over the course of treatment. The underlying motivation of this approach is to produce CEA estimates that reflect patient-level utilities and costs while adjusting for socio-demographic and clinical factors to aid patient-centered coverage and treatment decision-making. In the second approach, patient utilities are estimated based on the clinically defined health states through which a patient may transition throughout the course of treatment. While this approach is grounded on the widely used Markov transition model, we refine the model to facilitate an enhancement in conducting regression-based analysis to achieve transparent understanding of differences in utilities and costs across diverse patient populations. We discuss the unique statistical challenges of each approach and describe how these analytical strategies are related to non-regression-based models in health services research.
Literature
2.
go back to reference Kearns B, Ara R, Wailoo A. A review of the use of statistical regression models to inform cost effectiveness analyses within the NICE Technology Appraisals programme. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2012. Kearns B, Ara R, Wailoo A. A review of the use of statistical regression models to inform cost effectiveness analyses within the NICE Technology Appraisals programme. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2012.
3.
go back to reference Stirling B, Sofaer S, Siegelberg T, Gold M. Has the time come for cost-effectiveness analysis in US health care? Health Econ Policy Law. 2009;4:425–43.CrossRef Stirling B, Sofaer S, Siegelberg T, Gold M. Has the time come for cost-effectiveness analysis in US health care? Health Econ Policy Law. 2009;4:425–43.CrossRef
4.
go back to reference Garrison LP. Cost-effectiveness and clinical practice guidelines: have we reached a tipping point?—An overview. Value Health. 2016;19:512–5.CrossRefPubMed Garrison LP. Cost-effectiveness and clinical practice guidelines: have we reached a tipping point?—An overview. Value Health. 2016;19:512–5.CrossRefPubMed
5.
go back to reference Russell L. The science of making better decisions about health: cost-effectiveness and cost-benefit analysis. Rockville: Agency for Healthcare Research and Quality; 2015. Russell L. The science of making better decisions about health: cost-effectiveness and cost-benefit analysis. Rockville: Agency for Healthcare Research and Quality; 2015.
6.
go back to reference Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy A, Acharya A, Evans DB, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy A, Acharya A, Evans DB, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
7.
go back to reference Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;1310:1295–310.CrossRef Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;1310:1295–310.CrossRef
8.
go back to reference Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. Oxford: Oxford University Press; 2016. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. Oxford: Oxford University Press; 2016.
9.
go back to reference Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II—an ISPOR Good Research Practices Task Force report. Value Health. 2015;18:161–72.CrossRefPubMed Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II—an ISPOR Good Research Practices Task Force report. Value Health. 2015;18:161–72.CrossRefPubMed
10.
go back to reference Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–50.CrossRefPubMed Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–50.CrossRefPubMed
11.
go back to reference Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force Report. Value Health. 2005;8:521–33.CrossRefPubMed Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force Report. Value Health. 2005;8:521–33.CrossRefPubMed
12.
go back to reference Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—part III. Value Health. 2009;12:1062–73.CrossRefPubMed Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—part III. Value Health. 2009;12:1062–73.CrossRefPubMed
13.
go back to reference Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR Good Practices for Outcomes Research Task Force Report. Value Health. 2017;20(1):18–27. Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR Good Practices for Outcomes Research Task Force Report. Value Health. 2017;20(1):18–27.
14.
go back to reference Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10:326–35.CrossRefPubMed Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10:326–35.CrossRefPubMed
15.
go back to reference Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15:677–87.CrossRefPubMed Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15:677–87.CrossRefPubMed
17.
go back to reference Lorgelly PK, Doble B, Knott RJ, Cancer T. Realising the value of linked data to health economic analyses of cancer care: a case study of Cancer 2015. Pharmacoeconomics. 2016;34:139–54.CrossRefPubMed Lorgelly PK, Doble B, Knott RJ, Cancer T. Realising the value of linked data to health economic analyses of cancer care: a case study of Cancer 2015. Pharmacoeconomics. 2016;34:139–54.CrossRefPubMed
18.
go back to reference Hardy M, Bryman A, editors. Handbook of data analysis. 1st ed. London: SAGE Publications; 2009. Hardy M, Bryman A, editors. Handbook of data analysis. 1st ed. London: SAGE Publications; 2009.
19.
go back to reference Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–30.CrossRefPubMed Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–30.CrossRefPubMed
20.
go back to reference Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ. 2004;13:461–75.CrossRefPubMed Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ. 2004;13:461–75.CrossRefPubMed
21.
go back to reference Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283–95.CrossRefPubMed Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283–95.CrossRefPubMed
22.
go back to reference Lohr KN. Comparative effectiveness research methods: symposium overview and summary. Med Care. 2010;48:S3–6.CrossRefPubMed Lohr KN. Comparative effectiveness research methods: symposium overview and summary. Med Care. 2010;48:S3–6.CrossRefPubMed
23.
go back to reference Horn SD, Gassaway J. Practice-based evidence study design for comparative effectiveness research. Med Care. 2007;45:S50–7.CrossRefPubMed Horn SD, Gassaway J. Practice-based evidence study design for comparative effectiveness research. Med Care. 2007;45:S50–7.CrossRefPubMed
24.
go back to reference Horn SD, Gassaway J. Practice based evidence: incorporating clinical heterogeneity and patient-reported outcomes for comparative effectiveness research. Med Care. 2010;48:S17–22.CrossRefPubMed Horn SD, Gassaway J. Practice based evidence: incorporating clinical heterogeneity and patient-reported outcomes for comparative effectiveness research. Med Care. 2010;48:S17–22.CrossRefPubMed
25.
go back to reference Gold M, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. 1st ed. Oxford: Oxford University Press; 1996. Gold M, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. 1st ed. Oxford: Oxford University Press; 1996.
26.
go back to reference Feeny D, Krahn M, Prosser L, Salomon J. Valuing health outcomes. In: Newmann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. Oxford: Oxford University Press; 2017. p. 167–99. Feeny D, Krahn M, Prosser L, Salomon J. Valuing health outcomes. In: Newmann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. Oxford: Oxford University Press; 2017. p. 167–99.
27.
go back to reference Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. ISPOR Task Force report estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force report. Value Health. 2016;19:704–19.CrossRefPubMed Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. ISPOR Task Force report estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force report. Value Health. 2016;19:704–19.CrossRefPubMed
28.
go back to reference Dolan P, Roberts J. Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Med Care. 2002;40(5):442–6.CrossRefPubMed Dolan P, Roberts J. Modelling valuations for Eq-5d health states: an alternative model using differences in valuations. Med Care. 2002;40(5):442–6.CrossRefPubMed
29.
go back to reference Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ. Paltiel AD; ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15:835–42.CrossRefPubMed Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ. Paltiel AD; ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15:835–42.CrossRefPubMed
30.
go back to reference McMahon L, Newbold R. Variation in resource use within diagnosis-related groups: the effect of severity of illness and physician practice. Med Care. 1986;24:388–97.CrossRefPubMed McMahon L, Newbold R. Variation in resource use within diagnosis-related groups: the effect of severity of illness and physician practice. Med Care. 1986;24:388–97.CrossRefPubMed
31.
go back to reference Lo T, Parkinson L, Cunich M, Byles J. Factors associated with higher healthcare costs in individuals living with arthritis: evidence from the quantile regression approach. Expert Rev Pharmacoecon Outcomes Res. 2015;15:833–41.CrossRefPubMed Lo T, Parkinson L, Cunich M, Byles J. Factors associated with higher healthcare costs in individuals living with arthritis: evidence from the quantile regression approach. Expert Rev Pharmacoecon Outcomes Res. 2015;15:833–41.CrossRefPubMed
32.
go back to reference Furlong W, Feeny D, Torrance GW, Barr RD, Horsman J. Guide to design and development of health-state utility instrumentation. CHEPA Working Paper 90-9. Hamilton: McMaster University Centre for Health Economics and Policy Analysis; 1990. Furlong W, Feeny D, Torrance GW, Barr RD, Horsman J. Guide to design and development of health-state utility instrumentation. CHEPA Working Paper 90-9. Hamilton: McMaster University Centre for Health Economics and Policy Analysis; 1990.
33.
go back to reference Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005;6:93–109.CrossRefPubMed Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005;6:93–109.CrossRefPubMed
34.
go back to reference Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009;47:S109–14.CrossRefPubMed Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009;47:S109–14.CrossRefPubMed
35.
go back to reference McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics. 2000;17:501–13.CrossRefPubMed McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics. 2000;17:501–13.CrossRefPubMed
36.
go back to reference Hanley JA, Negassa A, deB Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157:364–75.CrossRefPubMed Hanley JA, Negassa A, deB Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157:364–75.CrossRefPubMed
37.
go back to reference Basu A. Extended generalized linear models: simultaneous estimation of flexible link and variance functions. Stata J. 2007;5:501–16. Basu A. Extended generalized linear models: simultaneous estimation of flexible link and variance functions. Stata J. 2007;5:501–16.
38.
go back to reference Stillman S. Review of generalized estimating equations by Hardin and Hilbe. Stata J. 2003;3:208–10. Stillman S. Review of generalized estimating equations by Hardin and Hilbe. Stata J. 2003;3:208–10.
39.
go back to reference Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton: Chapman & Hall/CRC; 2003. Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton: Chapman & Hall/CRC; 2003.
40.
go back to reference Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–430.CrossRefPubMed Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–430.CrossRefPubMed
41.
go back to reference Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed
42.
go back to reference Drummond M, Sculpher MJ, Torrance G, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond M, Sculpher MJ, Torrance G, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
43.
go back to reference Fenwick E, Briggs A. Cost-effectiveness analysis. In: Melnick E, Everitt B, editors. Encyclopedia of quantitative risk analysis and assessment. Hoboken: John Wiley & Sons Ltd; 2008. p. 375–87. Fenwick E, Briggs A. Cost-effectiveness analysis. In: Melnick E, Everitt B, editors. Encyclopedia of quantitative risk analysis and assessment. Hoboken: John Wiley & Sons Ltd; 2008. p. 375–87.
44.
go back to reference Liu L. Joint modeling longitudinal semi-continuous data and survival, with application to longitudinal medical cost data. Stata Med. 2009;28:972–86.CrossRef Liu L. Joint modeling longitudinal semi-continuous data and survival, with application to longitudinal medical cost data. Stata Med. 2009;28:972–86.CrossRef
45.
go back to reference Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
46.
go back to reference Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—part I. Value Health. 2009;12:1044–53.CrossRefPubMed Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—part I. Value Health. 2009;12:1044–53.CrossRefPubMed
47.
go back to reference Brookhart M, Sturmer T, Glynn R, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48:114–20.CrossRef Brookhart M, Sturmer T, Glynn R, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48:114–20.CrossRef
48.
go back to reference Jones AM, Lomas J, Moore PT, Rice N. A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs. J R Stat Soc Ser A. 2016;179:951–74.CrossRef Jones AM, Lomas J, Moore PT, Rice N. A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs. J R Stat Soc Ser A. 2016;179:951–74.CrossRef
49.
go back to reference Lunceford JK, Davidian M. Stratiÿcation and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23:2937–60.CrossRefPubMed Lunceford JK, Davidian M. Stratiÿcation and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23:2937–60.CrossRefPubMed
50.
go back to reference Newhouse J, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17–34.CrossRefPubMed Newhouse J, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17–34.CrossRefPubMed
51.
go back to reference Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Stat Methods Med Res. 2014;23:440–59.CrossRefPubMed Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Stat Methods Med Res. 2014;23:440–59.CrossRefPubMed
52.
go back to reference Small CG, Wang J. Numerical methods for nonlinear estimating equations. Oxford: Oxford University Press; 2003.CrossRef Small CG, Wang J. Numerical methods for nonlinear estimating equations. Oxford: Oxford University Press; 2003.CrossRef
Metadata
Title
Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis
Authors
Daisuke Goto
Ya-Chen Tina Shih
Pascal Lecomte
Melvin Olson
Chukwukadibia Udeze
Yujin Park
C. Daniel Mullins
Publication date
01-07-2017
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 7/2017
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-017-0505-5

Other articles of this Issue 7/2017

PharmacoEconomics 7/2017 Go to the issue